Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Hezode Christophe; Reau Nancy; Svarovskaia Evguenia S.; Doehle Brian P.; Shanmugam Ragavi; Dvory-Sobol Hadas; Hedskog Charlotte; McNally John; Osinusi Anu; Brainard Diana M.; Miller Michael D.; Mo Hongmei; Roberts Stuart K.; OLeary Jacqueline G.; Shafran Stephen D.; Zeuzem Stefan

首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

【24h】

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

机译：基因型1-6 HCV感染患者的抗性分析，用Sofosbuvir / Velpatasvir在III期研究中的研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background & Aims: The fixed-dose combination of sofosbuvir/velpatasvir was highly efficacious in patients infected with genotype (GT) 1-6 hepatitis C virus (HCV) in the ASTRAL studies. This analysis evaluated the impact of baseline resistance-associated substitutions (RASs) on treatment outcome and emergence of RASs in patients infected with HCV GT1-6 who were treated with sofosbuvir/velpatasvir.

机译：背景和目标：Sofosbuvir / VelpataSvir的固定剂量组合在星空研究中感染基因型（GT）1-6丙型肝炎病毒（HCV）的患者中非常有效。该分析评估了基线电阻相关取代（RASS）对治疗结果的影响，并用Sofosbuvir / VelpataSvir治疗的HCV GT1-6感染的患者的rass出现。

著录项

来源
《Journal of Hepatology: The Journal of the European Association for the Study of the Liver》 |2018年第5期|共9页
作者
Hezode Christophe; Reau Nancy; Svarovskaia Evguenia S.; Doehle Brian P.; Shanmugam Ragavi; Dvory-Sobol Hadas; Hedskog Charlotte; McNally John; Osinusi Anu; Brainard Diana M.; Miller Michael D.; Mo Hongmei; Roberts Stuart K.; OLeary Jacqueline G.; Shafran Stephen D.; Zeuzem Stefan;
展开▼
作者单位

Univ Paris Est Hop Henri Mondor AP HP INSERM U955 Serv Hepatol Creteil France;

Rush Univ Med Ctr Chicago IL 60612 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Alfred Hlth Melbourne Vic Australia;

Baylor Univ Med Ctr Dallas Dallas TX USA;

Univ Alberta Edmonton AB Canada;

Goethe Univ Frankfurt Med Ctr Frankfurt Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Direct-acting antivirals; Sofosbuvir/velpatasvir; ASTRAL-1; ASTRAL-2; ASTRAL-3; ASTRAL-5; POLARIS-2; POLARIS-3;

机译：直接抗病毒率;sofosbuvir / velpatasvir;星式-1;星式-2;星式-3;星式-5;北极星-2;polaris-3;polaris-3;

相似文献

外文文献
中文文献
专利

1. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies [J] . Hezode Christophe, Reau Nancy, Svarovskaia Evguenia S., Journal of Hepatology: The Journal of the European Association for the Study of the Liver . 2018,第5期

机译：基因型1-6 HCV感染患者的抗性分析，用Sofosbuvir / Velpatasvir在III期研究中的研究
2. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study [J] . Jacobson Ira M., Asselah Tarik, Nahass Ronald, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第6期

机译：在DAA初次感染1-6型HCV的患者中，Sofosbuvir / Velpatasvir / Voxilaprevir进行了8周的随机3期试验，与Sofosbuvir / Velpatasvir进行了12周的随机试验比较：POLARIS-2研究
3. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study [J] . Foster Graham R., Thompson Alex J., Ruane Peter J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir / Velpatasvir / Voxilaprevir的随机相3试验8周和Sofosbuvir / Velpatasvir为基因型3 HCV感染和肝硬化的患者进行12周：Polaris-3研究
4. HCV-related Factors but not HIV-Related Factors at Baseline Predict the Response to Treatment With Peginterferon alfa-2a (40KD) (PEGASYS) Plus Ribavirin (COPEGUS) in Patients With HCV/HIV Co-infection: Predictor Analysis From the APRICOT Study [C] . D. Cooper, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：HCV相关因素但基线上没有艾滋病毒相关因素预测与HCV / HIV共感染患者的Peginterferon Alfa-2a（40kd）（Pegasys）（Pegasys）加利巴韦林（Copegus）对治疗的反应：来自杏研究的预测因素分析
5. The impact of pharmacodynamic parameters on prediction of clinical outcome in HIV-1 infected patients and HCV patients with HIV co-infection. [D] . Kim, Tae Eun. 2012

机译：药效学参数对HIV-1感染的患者和HCV合并感染的HCV患者的临床结局预测的影响。
6. Original article: Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt [O] . Gamal Shiha, Gamal Esmat, Mohamed Hassany, -1

机译：原始文章：Ledipasvir / sofosbuvir联合或不联合利巴韦林治疗8或12周用于治疗HCV基因型4感染：来自埃及的一项随机III期研究结果
7. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial [O] . Gane, Edward J., Kowdley, Kris V., Pound, David, 2016

机译：在开放标签的2期试验中，Sofosbuvir，Velpatasvir和GS-9857在具有丙型肝炎病毒基因型2、3、4或6感染的患者中的疗效

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

摘要

著录项

相似文献

相关主题

期刊订阅